Thus, while PCOS can result from a variety of causes independent of HMGCR, our PheWAS results support the idea that alterations in the HMGCR/mevalonate pathway could be one promising target for treating the manifestations of this condition. Here, HMGCR is linked to polycystic ovary syndrome.